Hereditary transthyretin-mediated amyloid polyneuropathy

Clinical trials for Hereditary transthyretin-mediated amyloid polyneuropathy explained in plain language.

Never miss a new study

Get alerted when new Hereditary transthyretin-mediated amyloid polyneuropathy trials appear

Sign up with your email to follow new studies for Hereditary transthyretin-mediated amyloid polyneuropathy, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New drug shows promise for Long-Term control of rare nerve disease

Disease control Ongoing

This study looks at the long-term safety and effects of a drug called eplontersen in people with a rare inherited nerve disease called hATTR-PN. About 151 participants who completed earlier studies will receive regular injections of eplontersen. The goal is to see if the drug rem…

Matched conditions: HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOID POLYNEUROPATHY

Phase 3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control

Last updated Jun 27, 2026 08:01 UTC

Hereditary transthyretin-mediated amyloid polyneuropathy

Get alerted when new Hereditary transthyretin-mediated amyloid polyneuropathy trials appear

New drug shows promise for Long-Term control of rare nerve disease